Drugs / ertumaxomab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01569412 | Mar 2012 → May 2016 | — | Krankenhaus Nordwest | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00522457 | Jan 2008 → Dec 2009 | breast cancer | Neovii Biotech | Terminated | No outcome recorded |
| Phase 2 | NCT00452140 | Mar 2007 → Feb 2009 | breast cancer | Neovii Biotech | Terminated | No outcome recorded |
| Phase 2 | NCT00351858 | Jul 2006 → Feb 2009 | breast cancer | Neovii Biotech | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ertumaxomab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01569412 ↗ |
| Known as | ertu | “BACKGROUND: Ertumaxomab (ertu) is a bispecific, trifunctional antibody targeting Her2/neu, CD3 and the Fcγ-receptors I, IIa, and III forming a tri-cell complex between tumor...” PMID 27387446 ↗ Jul 2016 |
| Modality | Monoclonal antibody | “trifunctional anti-Her-2/neu x anti-CD3 antibody” NCT00351858 ↗ |
| Route | Intravenous | “administered intravenously” NCT00351858 ↗ |
| Target | CD3E | “T-cell surface glycoprotein CD3 epsilon chain cross-linking agent” CHEMBL2108029 ↗ |
| Target | ERBB2 | “Receptor protein-tyrosine kinase erbB-2 cross-linking agent” CHEMBL2108029 ↗ |